pravastatin has been researched along with Autoimmune Diabetes in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albano, A; Aronovitz, M; Galper, JB; Jin, H; Link, MS; Noujaim, SF; Park, HJ; Rajab, M; Welzig, CM; Zhang, Y | 1 |
| Casiano, H; Crespo, MJ; Cruz, N; Hernandez, C; Quidgley, J; Rivera, K; Torres, H | 1 |
| Carraway, JW; Gazda, LS; Hall, RD; Laramore, MA; Smith, BH; Vinerean, HV | 1 |
| Huang, C; Li, X; Lin, J; Yan, X; Yang, L; Zhang, S; Zhou, PC; Zhou, ZG | 1 |
| Harada, M; Otani, M; Otsuki, M; Yamamoto, M | 1 |
| Arnesen, H; Eid, HM; Eritsland, J; Larsen, J; Seljeflot, I | 1 |
| Bouchier-Hayes, DJ; Fennessy, F; Fitzgerald, P; Joyce, M; Kelly, CJ; Moore, K; Thompson, C | 1 |
| Ahotupa, M; Janatuinen, T; Knuuti, J; Nuutila, P; Raitakari, OT; Rönnemaa, T; Toikka, JO | 1 |
| Campesi, I; Emanueli, C; Gadau, S; Kraenkel, N; Madeddu, P; Meloni, M; Monopoli, A; Ongini, E | 1 |
| Bouchier-Hayes, DJ; Casey, RG; Fitzgerald, P; Joyce, M; Moore, K; Thompson, C | 1 |
| Cressman, MD; Ganda, OP; Lodewick, PA; McGovern, ME; Phillipson, B; Raskin, P; Rosenstock, J; Schwartz, S; Weiner, B; Willard, D | 1 |
| De Leeuw, I; Van Gaal, L; Vertommen, J; Zhang, A | 1 |
| Fonseca, VA; Gardner, SF; Granberry, MC; Marx, MA; Skelton, DR; White, LM | 1 |
| Janssens, EN; Rustemeijer, C; Schouten, JA; Spooren, PF; van Doormaal, JJ | 1 |
| Berrocal, M; Chang, S; Drexler, A; Gordon, B; Kavanagh, M; Robertson, C; Yannuzzi, L | 1 |
7 trial(s) available for pravastatin and Autoimmune Diabetes
| Article | Year |
|---|---|
Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin.
Topics: Arginine; Arteriosclerosis; Cholesterol, LDL; Diabetes Mellitus, Type 1; Female; Humans; Hypercholesterolemia; Incidence; Male; Pravastatin; Predictive Value of Tests; Probability; Reference Values; Risk Assessment; Sensitivity and Specificity | 2003 |
Effect of pravastatin on low-density lipoprotein oxidation and myocardial perfusion in young adults with type 1 diabetes.
Topics: Adult; Coronary Circulation; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Dipyridamole; Double-Blind Method; Female; Glucose Clamp Technique; Heart; Hemodynamics; Humans; Hyperinsulinism; Lipoproteins, LDL; Male; Oxidation-Reduction; Positron-Emission Tomography; Pravastatin; Retinal Vessels | 2004 |
Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes.
Topics: Adult; Blood Pressure; Brachial Artery; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pilot Projects; Pravastatin; Stroke Volume; Vasodilation | 2007 |
Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Postmenopause; Pravastatin; Treatment Outcome | 1995 |
Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients.
Topics: Adult; Alanine Transaminase; Albuminuria; Aspartate Aminotransferases; Creatine Kinase; Cross-Over Studies; Diabetes Mellitus, Type 1; Enzyme Inhibitors; Evaluation Studies as Topic; Female; gamma-Glutamyltransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Pravastatin | 1995 |
Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fructosamine; Humans; Hypercholesterolemia; Lipoprotein(a); Male; Middle Aged; Niacin; Pravastatin; Prospective Studies | 1997 |
Pravastatin in diabetes-associated hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipid Metabolism; Lipids; Male; Middle Aged; Pravastatin; Time Factors | 1997 |
8 other study(ies) available for pravastatin and Autoimmune Diabetes
| Article | Year |
|---|---|
Increased inducibility of ventricular tachycardia and decreased heart rate variability in a mouse model for type 1 diabetes: effect of pravastatin.
Topics: Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Pravastatin; Tachycardia, Ventricular | 2013 |
Daily administration of atorvastatin and simvastatin for one week improves cardiac function in type 1 diabetic rats.
Topics: Animals; Atorvastatin; Blood Glucose; Cardiac Output; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Administration Schedule; Heart; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Ventricular Function, Left | 2014 |
No evidence of viral transmission following long-term implantation of agarose encapsulated porcine islets in diabetic dogs.
Topics: Animals; Body Weight; C-Peptide; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dogs; Insulin; Islets of Langerhans; Male; Pravastatin; Sepharose; Swine; Time Factors | 2014 |
[Effects of pravastatin in prevention of diabetes and mechanism thereof: experiment with non-obese diabetic mice].
Topics: Animals; CD4 Lymphocyte Count; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukin-4; Islets of Langerhans; Mice; Mice, Inbred NOD; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Th1 Cells; Th2 Cells | 2008 |
Effect of long- and short-term treatments with pravastatin on diabetes mellitus and pancreatic fibrosis in the Otsuka-Long-Evans-Tokushima fatty rat.
Topics: Adipose Tissue, White; Animals; Apoptosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 1; Fatty Acids, Nonesterified; Fibrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Organ Size; Pancreas; Peroxidase; Pravastatin; Rats; Rats, Long-Evans; Superoxide Dismutase; Time Factors; Transforming Growth Factor beta1; Triglycerides; Tumor Necrosis Factor-alpha | 2010 |
Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 1; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pilot Projects; Pravastatin; Up-Regulation | 2004 |
Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb Ischaemia in type-1 diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Hindlimb; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ischemia; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Physiologic; Nitrates; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin | 2007 |
The effects of lipid lowering on diabetic retinopathy.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Dietary Fats; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Triglycerides; Visual Acuity | 1991 |